|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash, cash equivalents, and restricted cash | |||||||||||||||
| Receivables – net of allowances of $101 and $103 | |||||||||||||||
| Nonrelated party | |||||||||||||||
| Related party | |||||||||||||||
| Total receivables – net of allowances of $101 and $103 | |||||||||||||||
| Inventories | |||||||||||||||
| Contract and other deferred assets | |||||||||||||||
| All other current assets | |||||||||||||||
| Current assets | |||||||||||||||
| Property, plant, and equipment – net | |||||||||||||||
| Goodwill | |||||||||||||||
| Other intangible assets – net | |||||||||||||||
| Deferred income taxes | |||||||||||||||
| All other non-current assets | |||||||||||||||
| Related party | |||||||||||||||
| Total all other non-current assets | |||||||||||||||
| Total assets | |||||||||||||||
| Short-term borrowings | |||||||||||||||
| Accounts payable | |||||||||||||||
| Contract liabilities | |||||||||||||||
| Current compensation and benefits | |||||||||||||||
| All other current liabilities | |||||||||||||||
| Nonrelated party | |||||||||||||||
| Related party | |||||||||||||||
| Total all other current liabilities | |||||||||||||||
| Current liabilities | |||||||||||||||
| Long-term borrowings | |||||||||||||||
| Non-current compensation and benefits | |||||||||||||||
| All other non-current liabilities | |||||||||||||||
| Related party | |||||||||||||||
| Total all other non-current liabilities | |||||||||||||||
| Total liabilities | |||||||||||||||
| Redeemable noncontrolling interests | |||||||||||||||
| Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 459,920,180 shares issued as of September 30, 2026; 458,844,209 shares issued as of December 31, 2025 | |||||||||||||||
| Treasury stock, at cost, 7,785,199 shares as of September 30, 2026 and 3,107,626 shares as of December 31, 2025 | |||||||||||||||
| Additional paid-in capital | |||||||||||||||
| Retained earnings | |||||||||||||||
| Net parent investment | |||||||||||||||
| Accumulated other comprehensive income (loss) – net | |||||||||||||||
| Total equity attributable to GE HealthCare | |||||||||||||||
| Noncontrolling interests | |||||||||||||||
| Total equity | |||||||||||||||
| Total liabilities, redeemable noncontrolling interests, and equity | |||||||||||||||
Loading...